$14.96 0.00 (%) Depomed Inc - NASDAQ

Sep. 18, 2014 | 04:00 PM

Partner Headlines

  1. Shares Of Depomed Moving Higher

    Benzinga | Aug. 19, 2014 | 11:14AM EST
  2. DEPOMED

    IBD | Aug. 6, 2014 | 18:46PM EST
  3. Depomed May Be Setting Up In A New Base

    IBD | May. 6, 2014 | 17:17PM EST
  4. Depomed A 'Turtle' Gaining In Specialty Pharma Race

    IBD | Mar. 25, 2014 | 17:52PM EST
  5. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

    Benzinga | Mar. 17, 2014 | 04:42AM EST
  6. Mid-Day Market Update: Stocks Turn Mostly Lower; VeriFone Shares Fall On Downbeat Guidance

    Benzinga | Dec. 18, 2013 | 12:33PM EST
  7. UPDATE: JMP Securities Reiterates on Depomed Following Acquisition of Migraine Asset

    Benzinga | Dec. 18, 2013 | 09:35AM EST
  8. Depomed Acquires US Rights to CAMBIA Migraine Medicine from Nautilus Neurosciences for $48.7M

    Benzinga | Dec. 17, 2013 | 16:08PM EST
  9. UPDATE: Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5M

    Benzinga | Oct. 21, 2013 | 16:03PM EST
  10. Depomed Announces Acquisition Of Lazanda® (fentanyl) Nasal Spray From Archimedes Pharma Limited

    Benzinga | Jul. 29, 2013 | 16:10PM EST
  11. Depomed Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 5, 2012 | 11:11AM EST
  12. Depomed Appoints Dr. Samuel Saks To Its Board Of Directors

    Benzinga | Oct. 9, 2012 | 10:09AM EST
  13. Breeze 3 data for Serada presented at 2012 North American Menopause Society Annual Meeting

    Benzinga | Oct. 3, 2012 | 02:17AM EST
  14. Depomed Files Suit Against The FDA Seeking Grant Of Orphan Drug Exclusivity For Gralise

    Benzinga | Sep. 25, 2012 | 10:31AM EST
  15. Depomed Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 3, 2012 | 13:26PM EST
  16. Depomed Announces Publication of Phase 3 Data from Gralise® (gabapentin) Clinical Trial

    Benzinga | Jul. 23, 2012 | 02:04AM EST
  17. IHS, Ebix Included in Stocks Up on High Volume Friday

    FoxBusiness | Jun. 22, 2012 | 06:32AM EST
  18. Depomed Announces Acquisition Of Zipsor From Xanodyne Pharmaceuticals, Inc.

    Benzinga | Jun. 21, 2012 | 10:05AM EST
  19. Depomed Announces Issuance of Formulation Patent Covering Gralise® (gabapentin)

    Benzinga | Jun. 6, 2012 | 02:05AM EST
  20. Earnings Scheduled For May 8

    Benzinga | May. 7, 2012 | 18:31PM EST
  21. A Peek Into The Market Before The Trading Starts

    Benzinga | Mar. 5, 2012 | 00:21AM EST
  22. Benzinga's Top Pre-Market Gainers

    Benzinga | Feb. 6, 2012 | 01:10AM EST
  23. Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck

    Benzinga | Feb. 3, 2012 | 09:15AM EST
  24. Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise

    Benzinga | Jan. 23, 2012 | 09:30AM EST
  25. Options Players Gravitate Toward Depomed Puts

    SchaeffersResearch | Nov. 2, 2011 | 10:53AM EST
Trading Center